Researchers analyzed real-world data from 446 Chinese patients with psoriatic arthritis who received secukinumab for more than 12 weeks. The study focused on skin measures—PASI, BSA, and IGA scores—and dermatology-specific quality of life (DLQI). Over follow-up, average PASI scores improved significantly, dropping from 14.2 to about 4.0. The study also reported improvements in quality of life.
Because this was an observational cohort, the findings show an association rather than proof that secukinumab caused these changes. Safety data were limited; serious adverse events and discontinuations were not reported, and tolerability was not detailed.
The main reason to be cautious is the study design: retrospective, real-world data can be influenced by confounding factors. Results apply specifically to this Chinese psoriatic arthritis population and may not generalize to other groups.
Realistic takeaway: The study suggests secukinumab may be linked to skin benefits and better quality of life in Chinese psoriatic arthritis patients, but stronger evidence is needed to confirm cause and effect.
